33 results about "Glucosylceramides" patented technology

Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

The invention provides a geramide and/or glucosylceramide generating accelerant or humectant. The geramide and/or glucosylceramide generating accelerant or humectant takes black tea extracts selected from more than one of black brick tea, compressed tea after fermentation and Pu'er tea as effective components.

The invention provides a preparation method for producing promoter by ceramide and/or glucosylceramide, wherein a microbe of Yarrowia is cultured in a medium containing bean dregs and carbohydrate, and ceramide and/or glucosylceramide is obtained in a clear liquid to generate the promoter. According to the preparation method of the invention, the specific microbe is used, the by-product bean dregs in a food processing industry can be taken as a main raw material of the medium, thereby the promoter generated by the ceramide and and/or glucosylceramide can be obtained with low cost and high efficiency.

Certain embodiments provide a method of detecting one or more biomarkers in a subject having a lysosomal storage disorder, and the method comprises the steps: 1) measuring the concentration of a combination of two or more lipids in a sample from the subject, wherein the combination of lipids is selected from the group consisting of: a) a bis(monoacylglycero)phosphate (BMP); b) a GM2 ganglioside and/or a GM3 ganglioside; c) a GD3 ganglioside; d) a GD1a/b ganglioside; and e) a glucosylceramide (GlcCer); 2) measuring the concentration of GlcCer in a sample from the subject; 3) measuring the concentration of neurofilament light chain (Nf-L) in a sample from the subject; and/or 4) measuring the concentration of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in a sample from the subject.

The invention provides a manufacturing method of a ceramide generation accelerator and/or a glucosylceramide generation accelerator, wherein Pichia microorganisms are cultured in a culture medium containing beam dregs and saccharides, and the ceramide generation accelerator and/or the glucosylceramide generation accelerator are/is obtained from an obtained supernatant. According to the manufacturing method disclosed by the invention, by utilization of easily obtainable substances as the culture medium and specific microorganisms, the ceramide generation accelerator and/or the glucosylceramide generation accelerator can be acquired at low cost and high efficiency.

The present invention features compositions that include a fungal glucosylceramide (GlcCer) purified from a non-pathogenic fungus (e.g., Candida utilis) and, optionally, an adjuvant. The invention also features methods of treating a patient who has a fungal disease and methods of preventing a fungal disease in a subject by administration of these compositions. Also within the scope of the invention are methods of formulating a fungal vaccine by: (a) providing a fungal glucosylceramide isolated from a non-pathogenic fungus; and (b) combining the fungal glucosylceramide with an adjuvant in a physiologically acceptable excipient.

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

The invention provides a preparation method of a promoter for producing ceramide and/or glucosylceramide, wherein debaryomyces microbes are cultured in a culture medium containing bean dregs and saccharides, and the promoter for producing ceramide and/or glucosylceramide is obtained from the supernatant. According to the preparation method of the invention, special microbes are used, and bean dregs which are by products in food processing industry are used as a main raw material of the culture medium; therefore the promoter for producing ceramide and/or glucosylceramide is obtained with low cost and high efficiency.

The invention discloses a beautifying, whitening and spot-fading health-care product. The product comprises, by mass, 2-4 parts of grape polyphenols, 10-14 parts of hawthorn fruits, 3-5 parts of vitamin C, 3-7 parts of vitamin E, 1 part of procyanidine, 2 parts of beta-carotene, 2-4 parts of active iron, 15-20 parts of pectin, 2-5 parts of protein, 5-8 parts of provitamin A, 2-4 parts of mucoprotein, 3-6 parts of glucosylceramide, 5-6 parts of tranexamic acid, 7-9 parts of natural astaxanthin, 3-5 parts of vitamin C (VC), 3-5 parts of calcium pantothenate, 2-4 parts of L-vitamin C, 2-3 parts of arbutin, 4-6 parts of L-serine and 3-7 parts of hyaluronic acid. The product has the advantages that through the tranexamic acid, melanin and pigmented spots are prevented from being formed, the melanin transmission path is blocked, the skin of a user is whiter, and spots are faded; the glucosylceramide can make the skin of the user bright, and the health-care and whitening effects are better.

The invention discloses a method for screening an antifungal substance acting on glucosylceramide as a target. The method provided by the invention includes the following steps: a wild fungus strain and a mutant strain are respectively cultured on solid plates containing a substance to be assayed, and if the growth of the mutant strain on the plate is better than the growth of the wild fungus strain on the plate, the substance to be assayed is a candidate antifungal substance or a candidate substance containing the antifungal substance; and the target of the antifungal substance is glucosylceramide. The method established by the invention has the advantages that: the target is specific, moreover, the method integrates in vivo screening and activity assay, whether the substance is the antifungal substance targeting glucosylceramide can be judged only according to the difference between the sensitivities of the mutant strain and the wide strain on the antifungal substance, the screening process is simpler, and can save time and labor, and the result is more accurate and reliable. The method has a great application prospect in the screening and development of green control agents for fungal diseases.

The disclosure relates to compositions and methods for adding beta glucosylceramide and/or Cremophor EL (CE), or an adjuvant selected from polyethylene glycol and beta cyclo dextrin or any type of beta or alpha glucosylceramide with/without CE, or CE alone, to drinks or foods to serve as liver protectors, sugar protectors, and anti inflammatory protectors.